Mesoblast Ltd (MESO.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2007||Independent Non-Executive Chairman of the Board|
|2014||Chief Executive Officer, Executive Director|
|2016||Vice Chairman of the Board|
|2014||Group Chief Financial Officer|
|2011||General Counsel, Corporate Executive|
- BRIEF-Mesoblast Says Granted Tigenix Access To Certain Of Its Patents
- BRIEF-Tigenix Nv - Mesoblast Grants Access To Patents To Support Commercialization Of Adipose-Derived Mesenchymal Stem Cell Product Cx601 For Treatment Of Fistulae
- BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
- BRIEF-Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment
- BRIEF-Mesoblast posts FY loss attributable of $76.8 mln